Evidence map›Paper›PMID 35165144›Full record

ArticleThorax2022

Lung directed antibody gene transfer confers protection against SARS-CoV-2 infection.

Yue Du, Kamran M Miah, Omar Habib, Helena Meyer-Berg, Catriona C Conway, Mariana A Viegas, Rebecca Dean, Dwiantari Satyapertiwi, Jincun Zhao, Yanqun Wang and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thorax, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Progress in Respiratory Gene Therapy.Human gene therapy · 2022
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Yue DuNDCLS, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Kamran M MiahNDCLS, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Omar HabibNDCLS, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Helena Meyer-BergNDCLS, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Catriona C ConwayNDCLS, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Mariana A ViegasNDCLS, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Rebecca DeanNDCLS, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Dwiantari SatyapertiwiNDCLS, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Jincun ZhaoNational Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, Guangdong, China.
Yanqun WangNational Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, Guangdong, China.
Nigel J TempertonMedway School of Pharmacy, University of Kent, Canterbury, UK.
Toby P E GamlenNDCLS, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Deborah R GillNDCLS, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Stephen C HydeNDCLS, Radcliffe Department of Medicine, University of Oxford, Oxford, UK steve.hyde@ndcls.ox.ac.uk.
University of Oxford · GBFirst Affiliated Hospital of Guangzhou Medical University · CNState Key Laboratory of Respiratory Disease · CNUniversity of Kent · GB

Funding

Wellcome Trust 110579/Z/15/Z
6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic continues to be a worldwide threat and effective antiviral drugs and vaccines are being developed in a joint global effort. However, some elderly and immune-compromised populations are unable to raise an effective immune response against traditional vaccines.

aimsWe hypothesised that passive immunity engineered by the in vivo expression of anti-SARS-CoV-2 monoclonal antibodies (mAbs), an approach termed vectored-immunoprophylaxis (VIP), could offer sustained protection against COVID-19 in all populations irrespective of their immune status or age.

methodsWe developed three key reagents to evaluate VIP for SARS-CoV-2: (i) we engineered standard laboratory mice to express human ACE2 via rAAV9 in vivo gene transfer, to allow in vivo assessment of SARS-CoV-2 infection, (ii) to simplify in vivo challenge studies, we generated SARS-CoV-2 Spike protein pseudotyped lentiviral vectors as a simple mimic of authentic SARS-CoV-2 that could be used under standard laboratory containment conditions and (iii) we developed in vivo gene transfer vectors to express anti-SARS-CoV-2 mAbs.

conclusionsA single intranasal dose of rAAV9 or rSIV.F/HN vectors expressing anti-SARS-CoV-2 mAbs significantly reduced SARS-CoV-2 mimic infection in the lower respiratory tract of hACE2-expressing mice. If translated, the VIP approach could potentially offer a highly effective, long-term protection against COVID-19 for highly vulnerable populations; especially immune-deficient/senescent individuals, who fail to respond to conventional SARS-CoV-2 vaccines. The in vivo expression of multiple anti-SARS-CoV-2 mAbs could enhance protection and prevent rapid mutational escape.

Indexed as

COVID-19AgedAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansLungMicePandemicsSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19respiratory infectionviral infection

Identifiers

PMID35165144
PMCPMC8861887
OpenAlexW4212816675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.